Stay updated with the latest novo-nordisk news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on novo-nordisk topics.
Indian brides are turning to low-cost weight-loss injections ahead of their weddings. Freepik ShowQuick Read Summary is AI-generated, newsroom-reviewed * Soon-to-be Indian brides and grooms increasingly seek weight-loss drugs before weddings * Mounjaro is preferred over Wegovy and prescribed only for medically eligible patients * Regulators warn against misuse amid cheaper local weight-loss drug versions flooding market Did our AI summary help? Let us know. Switch To Beeps Mode Soon-to ...Read More >
March 31 (Reuters) - Novo Nordisk has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off competition from cheaper generics made by local drugmakers. India's market for diabetes and weight-loss drugs is set for a shake-up after the Danish drugmaker's patent on semaglutide, the active component in Ozempic and Wegovy, expired on March 20. At least half a dozen Indian drugmakers, including Dr Reddy's, Zydus an ...Read More >
HYDERABAD, India, April 3 (Reuters) - Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers. In a social media video, Klarity offers "guided nutrition, Mounjar ...Read More >
HYDERABAD, India, April 3 (Reuters) - Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers. In a social media video, Klarity offers "guided nutrition, Mounjaro ...Read More >
Bangalore : Emcure Pharmaceuticals Ltd., (BSE: 544210, NSE: EMCURE) has announced the price revision of its weight management drug Poviztra® (semaglutide injection) across India. The reduced price would be starting at Rs. 3,999/- per month (4 weekly doses). The innovator Semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple admini ...Read More >
HYDERABAD: Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers. In a social media video, Klarity offers "guided nutrition, Mounjaro and smart workouts" to prepa ...Read More >
HYDERABAD: Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers. Also Read: Weight-loss drug boom: Will cheaper Ozempic generics shake up India's fitness and nut ...Read More >
Mumbai: Emcure Pharmaceuticals has reduced the price of its weight management drug Poviztra (semaglutide injection) across India by an average of 47% across dosages in a bid to widen patient access. The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg with the highest dose priced at Rs 8,999 for a month's supply. Em ...Read More >
New Delhi, Apr 2 (PTI) Emcure Pharmaceuticals on Thursday announced a reduction in the price of its weight management drug, Poviztra, a semaglutide injection, by up to 55 per cent to expand patient access. The starting dose of Poviztra (0.25 mg) will now be available at Rs 3,999 per month (inclusive of taxes), a reduction of 55 per cent from the previous price of Rs 8,790, with the price reduction effective from April 3, 2026. Across all doses, the price of Poviztra has been reduced by an aver ...Read More >
New Delhi, Mar 31 (PTI) Novo Nordisk India on Tuesday announced price reductions for Ozempic and Wegovy in India, days after the launch of generic versions of semaglutide injections for patients living with type 2 diabetes and obesity. Indian pharma majors recently announced the launch of their generic versions following the molecule behind products like Ozempic and Wegovy, going off patent in India. Effective April 1, 2026, the price of the starting dose of Ozempic will be reduced by 36 per c ...Read More >
Mumbai city (area under Brihanmumbai Municipal Corporation or BMC jurisdiction) recorded 15,516 property registrations in March 2026, the highest monthly registration for March in 14 years, according to data from the Maharashtra Department of Registrations and Stamps analysed by Knight Frank India. The registrations in March 2026 generated over ₹1,492 crore in stamp duty revenue for the state exchequer. The registrations include both new sales and re-sales. On a year-on-year (Y-o-Y) basis, reg ...Read More >
A ₹1,000 crore market is set to grow 5x to ₹5,000 crore by 2030 as prices drop 40-50% post patent expiry. Three early movers are taking sharply different routes -- low-cost, premium, and partnerships in a high-stakes land grab. The Indian market for Glucagon-Like Peptide-1 (GLP-1) therapies is currently at an inflection point and is poised for strong expansion. The current market size for anti-obesity and diabetes GLP-1 drugs in India, as of 2025, is estimated to be between ₹1,000-1,200 cr ...Read More >
(Reuters) -Eli Lilly will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, as it seeks to tap into skilled workforce to bolster its global manufacturing expansion. The collaborations aim to increase the availability of Lilly's key drugs, including those for obesity, diabetes, Alzheimer's, cancer and autoimmune conditions, the company said. "We are making significant investments to increase manufactu ...Read More >
Mumbai: Less than a month after Ozempic maker Novo Nordisk announced it is cutting its global workforce as part of a restructuring plan, the layoffs have hit Indian employees in Bengaluru. Junior- to mid-level employees across functions such as sales and marketing, as well as those in the company's global business services (GBS) hub, which works with its global teams, have been impacted, according to at least three people aware of the development. "At least 100-150 will be retrenched from the ...Read More >
India has officially approved the use of Ozempic (semaglutide), a once-a-week injection designed for adults with type 2 diabetes. Approved by the Central Drugs Standard Control Organisation (CDSCO), this drug has made headlines worldwide not just for diabetes management but also for its weight loss effects. As India faces rising rates of diabetes, Ozempic's arrival is more than just a medical update, it could influence lifestyle choices for millions.Here's all we need to know about what this new ...Read More >
New Delhi, Sep 30 (PTI) India's drug regulator Central Drugs Standard Control Organisation (CDSCO) has approved Ozempic (semaglutide injection) manufactured by Danish pharma company Novo Nordisk for use in adults with type-2 diabetes. According to sources, Ozempic, the once-a-week injection, will be available only on a doctor's prescription. "Semaglutide Injection (Ozempic@) is indicated for the treatment of adults with Insufficiently Controlled Type 2 Diabetes Mellitus as an adjunct to Diet a ...Read More >
New Delhi [India], September 30 (ANI): The Central Drugs Standard Control Organisation (CDSCO) has approved Danish drugmaker Novo Nordisk's once-a-week injection for patients suffering from Type 2 diabetes. Also Read | Durga Puja 2025: PM Narendra Modi Participates in Durga Puja Celebrations in Delhi's CR Park on Occasion of Maha Ashtami, Prays for Everyone's Happiness and Wellbeing (See Pics). In a statement provided to ANI, Novo Nordisk has stated that Ozempic is intended for individuals wit ...Read More >
MUMBAI, Sept 25 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to bring its experimental oral weight-loss drug orforglipron to India as it sees market potential in the world's most populous nation, a senior executive said on Thursday. "I do think there is promise for products like that (orforpligron) in India, if it does get approved," Winselow Tucker, Lilly India's president said at an event in Mumbai. Tucker, however, did not indicate when Lilly plans to launch the drug. The drugmaker h ...Read More >
New Delhi [India], August 22 (ANI): India drug regulator has alerted on the theft of multiple drug products of Novo Nordisk during transit. According to the notice issued by the Drugs Controller General of India (DCGI), Dr Rajeev Raghuvanshi, Mis Novo Nordisk has informed about a theft of its products, as mentioned below, during transit from its Bhiwandi Hub to milk route (Nagpur, Raipur, Cuttack, and Kolkata). The DCGI has also mentioned in the notice that the quality of the injectables is re ...Read More >
Aug 1 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its shares up nearly 3% in premarket trading. Investors have set a high bar for Regeneron and French partner Sanofi's (SASY.PA), opens new tab Dupixent, one of the U.S. drugmaker's growth drivers, especially after it received approval to treat a common lung condition called c ...Read More >
New Delhi [India], July 16 (ANI): The Indian government expressed regret on Tuesday over the reported demolition of the ancestral property of celebrated filmmaker and writer Satyajit Ray in Mymensingh, Bangladesh and expressed its willingness to extend cooperation in its restoration. "We note with profound regret that the ancestral property of noted filmmaker and litterateur Satyajit Ray in Mymensingh, Bangladesh, belonging to his grandfather and eminent litterateur, Upendra Kishor Ray Chowdhur ...Read More >
India Diabetes Market: By Type; By Treatment Type; By Doses Form; Route of Administration; By End User; By Distribution Channel; Supplier Landscape; 2025-2034 The India diabetes market attained a value of approximately INR 316.00 Billion in 2024. The market is projected to grow at a compound annual growth rate (CAGR) of 16.00% during the forecast period of 2025-2034, reaching an estimated value of around INR 1394.01 Billion by 2034. The rising prevalence of diabetes, driven by sedentary lifesty ...Read More >
New Delhi, July 11 (SocialNews.XYZ) Despite volatility and chaos in the US stock market in the Q2 (April-June) period this year, Indian investors doubled down on their investments in shares of leading US companies, a report said on Friday. The April-June quarter was anything but ordinary for the US stock market, even as the S&P 500 plummeted 13 per cent in April after President Donald Trump's 'Liberation Day' tariff shock. The volatility spiked to crisis level before it started softening after ...Read More >
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular weight-loss drug Wegovy over fears of falling behind rival Eli Lilly in the potentially huge market, two sources familiar with the plans told Reuters. Officials at the Danish drugmaker have said Wegovy might be introduced in India in 2026 once regulatory approvals are in hand and there is sufficient supply. More recently, Novo's India team proposed moving the launch to nex ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.